Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting
Patients with pulmonary arterial hypertension (PAH) who are admitted to the hospital pose a challenge to the multidisciplinary healthcare team due to the complexity of the pathophysiology of their disease state and PAH-specific medication considerations. Pulmonary arterial hypertension is a progress...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-02-01
|
| Series: | Journal of Cardiovascular Pharmacology and Therapeutics |
| Online Access: | https://doi.org/10.1177/10742484231225310 |
| _version_ | 1827348066356690944 |
|---|---|
| author | Heather Torbic PharmD, FCCM, BCPS, BCCCP Adriano R. Tonelli MD, MSc |
| author_facet | Heather Torbic PharmD, FCCM, BCPS, BCCCP Adriano R. Tonelli MD, MSc |
| author_sort | Heather Torbic PharmD, FCCM, BCPS, BCCCP |
| collection | DOAJ |
| description | Patients with pulmonary arterial hypertension (PAH) who are admitted to the hospital pose a challenge to the multidisciplinary healthcare team due to the complexity of the pathophysiology of their disease state and PAH-specific medication considerations. Pulmonary arterial hypertension is a progressive disease that may lead to death as a result of right ventricular (RV) failure. During acute on chronic RV failure it is critical to decrease the pulmonary vascular resistance with the goal of improving RV function and prognosis; therefore, aggressive PAH-treatment based on disease risk stratification is essential. Pulmonary arterial hypertension treatment for acute on chronic RV failure can be impacted by end-organ damage, hemodynamic instability, drug interactions, and PAH medications dosage and delivery. Sotatercept, a first in class activin signaling inhibitor that works on the bone morphogenetic protein/activin pathway is on track for Food and Drug Administration approval for the treatment of PAH based on results of recent trials in where the medication led to clinical and hemodynamic improvements, even when added to traditional PAH-specific therapies. The purpose of this review is to highlight important considerations when starting or continuing sotatercept in patients admitted to the hospital with PAH. |
| first_indexed | 2024-03-08T00:04:36Z |
| format | Article |
| id | doaj.art-edfcd62cd4454c209cb9253b9e292eb0 |
| institution | Directory Open Access Journal |
| issn | 1940-4034 |
| language | English |
| last_indexed | 2024-03-08T00:04:36Z |
| publishDate | 2024-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Cardiovascular Pharmacology and Therapeutics |
| spelling | doaj.art-edfcd62cd4454c209cb9253b9e292eb02024-02-17T11:03:23ZengSAGE PublishingJournal of Cardiovascular Pharmacology and Therapeutics1940-40342024-02-012910.1177/10742484231225310Sotatercept for Pulmonary Arterial Hypertension in the Inpatient SettingHeather Torbic PharmD, FCCM, BCPS, BCCCP0Adriano R. Tonelli MD, MSc1 Department of Pharmacy, , Cleveland, OH, USA Department of Pulmonary, Allergy and Critical Care Medicine, , Cleveland, OH, USAPatients with pulmonary arterial hypertension (PAH) who are admitted to the hospital pose a challenge to the multidisciplinary healthcare team due to the complexity of the pathophysiology of their disease state and PAH-specific medication considerations. Pulmonary arterial hypertension is a progressive disease that may lead to death as a result of right ventricular (RV) failure. During acute on chronic RV failure it is critical to decrease the pulmonary vascular resistance with the goal of improving RV function and prognosis; therefore, aggressive PAH-treatment based on disease risk stratification is essential. Pulmonary arterial hypertension treatment for acute on chronic RV failure can be impacted by end-organ damage, hemodynamic instability, drug interactions, and PAH medications dosage and delivery. Sotatercept, a first in class activin signaling inhibitor that works on the bone morphogenetic protein/activin pathway is on track for Food and Drug Administration approval for the treatment of PAH based on results of recent trials in where the medication led to clinical and hemodynamic improvements, even when added to traditional PAH-specific therapies. The purpose of this review is to highlight important considerations when starting or continuing sotatercept in patients admitted to the hospital with PAH.https://doi.org/10.1177/10742484231225310 |
| spellingShingle | Heather Torbic PharmD, FCCM, BCPS, BCCCP Adriano R. Tonelli MD, MSc Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting Journal of Cardiovascular Pharmacology and Therapeutics |
| title | Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting |
| title_full | Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting |
| title_fullStr | Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting |
| title_full_unstemmed | Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting |
| title_short | Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting |
| title_sort | sotatercept for pulmonary arterial hypertension in the inpatient setting |
| url | https://doi.org/10.1177/10742484231225310 |
| work_keys_str_mv | AT heathertorbicpharmdfccmbcpsbcccp sotaterceptforpulmonaryarterialhypertensionintheinpatientsetting AT adrianortonellimdmsc sotaterceptforpulmonaryarterialhypertensionintheinpatientsetting |